T1	Participants 40 64	persistent genital warts
T2	Participants 192 249	recurrence of genital warts following destructive therapy
T3	Participants 326 429	recurrent genital warts amenable to destructive therapy, conducted independently in Australia and China
T4	Participants 760 826	33 protocol compliant Brisbane recipients of placebo immunotherapy
T5	Participants 1033 1096	102 protocol compliant Brisbane recipients of VLP immunotherapy
T6	Participants 1689 1764	168 Wenzhou protocol compliant subjects who also received VLP immunotherapy
T7	Participants 1897 1990	clearance of recurrent genital warts in patients for whom destructive therapy is unsuccessful
